Thermo Fisher Scientific Inc.
NYSE · Healthcare
| Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | |||||||||||||||||||
| Operating Cash Flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Income | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amort. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Comp. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Changes in WC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Investing | |||||||||||||||||||
| Capital Expenditures | 1.52B | 1.40B | 1.48B | 2.24B | 2.52B | 1.47B | 926.0M | 758.0M | 508.0M | 444.0M | 423.0M | 427.6M | 282.4M | 315.1M | 260.9M | 245.4M | 200.0M | 264.4M | 175.5M |
| Acquisitions | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Investing Cash Flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing | |||||||||||||||||||
| Debt Repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Common Stock Issued | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Summary | |||||||||||||||||||
| Free Cash Flow | 6.29B | 7.27B | 6.93B | 6.91B | 6.79B | 6.82B | 4.05B | 3.79B | 3.50B | 2.81B | 2.52B | 2.19B | 1.73B | 1.72B | 1.43B | 1.25B | 1.46B | 1.16B | 1.31B |
| Net Change in Cash | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |